Researchers reported that a multiplexed enhanced FRET-FLIM-based assay (QF-Pro) can stratify pre-treatment immune checkpoint interaction profiles to predict response to atezolizumab in urothelial carcinoma. In a tissue microarray cohort of 46 patients, interactions among PD-1/PD-L1 and CTLA-4/CD80 showed divergent associations with clinical outcomes. The findings suggest that a combination of high PD-1/PD-L1 engagement with low CTLA-4/CD80 interaction correlated with the best progression-free survival signal in the analysis. The study underscores the continued search for biomarkers that outperform single-measure approaches in combination-immunotherapy-era decision making. For development teams, the work supports further clinical utility testing of spatial/interaction-based checkpoint biomarkers and may influence how future trials incorporate mechanistic immune profiling rather than only surface marker expression.